**Disclaimer: Information on Semaglutide and Tirzepatide for Weight Loss**

The following disclaimer provides an overview of Semaglutide and Tirzepatide, including common side effects, contraindications, safety data, and efficacy for weight loss. It is essential to consult a qualified healthcare professional for personalized medical advice and treatment options.

Semaglutide:

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes. It has also been studied for its potential in weight management.

Common Side Effects: Side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and headache.

Contraindications: Semaglutide is contraindicated in patients with a history of severe gastrointestinal disease, pancreatitis, or a personal or family history of medullary thyroid carcinoma (MTC).

Safety Data: Safety data for weight management with semaglutide indicates potential risks, including gastrointestinal adverse events and pancreatitis. Long-term safety and efficacy data are still being evaluated.

Efficacy for Weight Loss: Clinical trials have shown promising results for weight loss with semaglutide. Patients may experience significant weight reduction compared to placebo, along with improvements in cardiometabolic risk factors.

WARNING *This medication is NOT insulin and should not be used if you have type 1 diabetes OR if you develop diabetic ketoacidosis. Semaglutide should not be used with any other GLP-1 medications.

Tirzepatide:

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist under investigation for the treatment of type 2 diabetes and obesity.

Common Side Effects: Side effects may include gastrointestinal disturbances (such as nausea, vomiting, and diarrhea), hypoglycemia, injection site reactions, and potential weight loss.

Contraindications: Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Safety Data: Safety data for tirzepatide is still emerging as clinical trials progress. Adverse events such as gastrointestinal symptoms and hypoglycemia have been reported, and long-term safety requires further investigation.

Efficacy for Weight Loss: Early clinical trials suggest tirzepatide may offer significant weight loss benefits for individuals with obesity, along with improvements in glycemic control and other metabolic parameters. Benefits of Tirzepatide may include: Decreased appetite and cravings, Weight loss, A1C reduction, Improved cardiometabolic measure.

WARNING *This medication is NOT insulin and should not be used if you have type 1 diabetes OR if you develop diabetic ketoacidosis. Tirzepatide should not be used with any other GLP-1 medications.

Individual results will vary. Compounded medications are not FDA regulated for quality, efficacy or safety.

**Disclaimer:**

The information provided herein is for educational and informational purposes only and should not be construed as medical advice. Individual responses to treatment may vary, and healthcare decisions should be made in consultation with a qualified healthcare professional. The safety and efficacy of Semaglutide and Tirzepatide for weight management are subject to ongoing research and regulatory review. Patients are advised to discuss potential risks and benefits with their healthcare provider before initiating treatment.